Risk of infections in patients with pemphigus treated with rituximab vs. azathioprine or mycophenolate mofetil: a large-scale global cohort study
British Journal of Dermatology · 2023
DOI: 10.1093/bjd/ljac118 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift British Journal of Dermatology, 2023. Verfasst von Khalaf Kridin und 3 weiteren Autor:innen. Beteiligte Einrichtung: Lübeck Institute of Experimental Dermatology, University of Lübeck, Lübeck, Germany. Hauptthemen laut MEDLINE: Pemphigus, COVID-19, Cytomegalovirus Infections. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 53 Literaturangaben.
Abstract (Originalsprache)
Background
The risk of infectious complications among patients with pemphigus managed by rituximab is yet to be precisely elucidated.
Objectives
To evaluate the risk of infections in patients with pemphigus managed by rituximab vs. first-line corticosteroid-sparing agents [azathioprine and mycophenolate mofetil (MMF)].
Methods
A global population-based cohort study compared patients with pemphigus initiating rituximab (n = 963) vs. azathioprine or MMF (n = 963) regarding the risk of 26 different infections. Propensity score matching was conducted to optimize comparability.
Results
During the initial 12 months following treatment, patients under rituximab experienced elevated risk of COVID-19 [hazard ratio (HR) 1.82, 95% confidence interval (CI) 1.06–3.14; P = 0.028], parasitic diseases (HR 3.22, 95% CI 1.04–9.97; P = 0.032) and cytomegalovirus (CMV) infection (HR 1.63, 95% CI 1.04–2.58; P = 0.033). When evaluating infections developing ≥ 12 months after drug initiation, rituximab was associated with greater risk of pneumonia (HR 1.45, 95% CI 1.00–2.10; P = 0.047), COVID-19 (HR 1.87, 95% CI 1.49–2.33; P < 0.001), osteomyelitis (HR 2.42, 95% CI 1.11–5.31; P = 0.023), herpes simplex virus (HR 2.06, 95% CI 1.03–4.11; P = 0.037) and CMV (HR 1.63, 95% CI 1.07–2.49; P = 0.023) infections.
Conclusions
Within the first 12 months after treatment, patients under rituximab experience an elevated risk of COVID-19, parasitic and CMV infections. Rituximab is associated with pneumonia, osteomyelitis and viral diseases even beyond the first year after therapy. Pneumococcal vaccine and suppressive antiviral therapy should be considered even 1 year following therapy. There is no signal for elevated risk of tuberculosis, hepatitis B virus reactivation, Pneumocystis jiroveci pneumonia and progressive multifocal leukoencephalopathy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Lübeck Institute of Experimental Dermatology, University of Lübeck, Lübeck, Germany.
- Azrieli Faculty of Medicine, Bar-Ilan University, Safed, Israel.
- Unit of Dermatology and Skin Research Laboratory, Barch Padeh Medical Center, Poriya, Israel.
- Division of Dermatology, Rush University Medical Center, Chicago, IL, USA.
- Department of Dermatology, University of Lübeck, Lübeck, Germany.
ORCID-Profile: Khalaf Kridin
Zitieren
APA
Kridin, K., Mruwat, N., Amber, K. T., & Ludwig, R. J. (2023). Risk of infections in patients with pemphigus treated with rituximab vs. azathioprine or mycophenolate mofetil: a large-scale global cohort study. British Journal of Dermatology. https://doi.org/10.1093/bjd/ljac118
Vancouver
Kridin K, Mruwat N, Amber KT, Ludwig RJ. Risk of infections in patients with pemphigus treated with rituximab vs. azathioprine or mycophenolate mofetil: a large-scale global cohort study. British Journal of Dermatology. 2023. doi:10.1093/bjd/ljac118
BibTeX
@article{Kridin2023,
author = {Kridin, Khalaf and Mruwat, Noor and Amber, Kyle T and Ludwig, Ralf J},
title = {Risk of infections in patients with pemphigus treated with rituximab vs. azathioprine or mycophenolate mofetil: a large-scale global cohort study},
journal = {British Journal of Dermatology},
year = {2023},
doi = {10.1093/bjd/ljac118}
}
EUVIMED